Pyxus International announced a private offer to exchange its outstanding 8.50% Senior Secured Notes due 2027 for a combination of new common stock and floating rate senior secured notes. The offer includes an early tender option with higher equity and note consideration, expiring December 10, 2026. The company is also soliciting consents to amend the existing indenture to remove restrictive covenants, subordinate the existing notes to new debt, and release collateral securing the notes. This restructuring aims to improve financial flexibility and is supported by major creditors holding a significant portion of the debt. The exchange and consent solicitation are subject to conditions including minimum participation and requisite consents, with settlement expected around December 15, 2026.
Pyxus International's exchange offer and consent solicitation provide context for market activity. For readers following US stocks on Pluang as of Nov 10, 2026 18:12 WIB: out of 150 priced stocks, 76 rose and 62 fell. Li Auto Inc (LI) gained 3.36% to USD 12.76 with a typical hold time of 104 days and predominantly buy orders (98%), contrasting with Lucid Group Inc (LCID) which dropped 3.33% to USD 3.48 and a shorter hold time of 46 days. Plug Power Inc (PLUG) rose 2.67% to USD 1.54 but saw mostly sell orders (72%) and a hold time of 43 days.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
